- Participant must have a confirmed diagnosis of untreated AML, should not be a candidate for standard therapy, and a clinical trial is a preferred treatment option or acute AML that is relapsed or refractory to no more than 2 prior induction regimens. Hydroxyurea to control prior blast counts is not considered a prior regimen.